Cemiplimab Combo Falls Short Versus Anti-PD-1 Monotherapy in HNSCC

The PD-1 inhibitor cemiplimab (Libtayo) in combination with radiotherapy, cyclophosphamide, and GM-CSF did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), according to results from a phase I expansion cohort that were presented at the 2018 ESMO Congress.

The investigators concluded that the use of cemiplimab in combination with radiotherapy, cyclophosphamide, and GM-CSF did not show greater efficacy than what has been achieved with other PD-1 inhibitor monotherapies in patients with recurrent or metastatic HNSCC.

---

... to read the full story